. | PRIBA (n = 254) . | CPRD (n = 23,001) . |
---|---|---|
Characteristics | ||
Baseline HbA1c (mmol/mol) | 74 (12) | 72 (15) |
Baseline HbA1c (%) | 8.9 (1.1) | 8.7 (1.3) |
Age at therapy start (years) | 63 (10) | 64 (11) |
Age at diagnosis (years) | 54 (10) | 56 (10) |
Male sex, % | 63 | 61 |
Duration of diabetes (years) | 9 (6) | 8 (5) |
BMI | 32 (29–37); 33 (6) | 32 (28–36); 33 (6) |
Ethnicity, % | ||
White | 97 | 45 |
Nonwhite | 3 | 6 |
Missing | 0 | 49 |
Biomarkers | ||
Triglycerides (mmol/L) | 1.7 (1.2–2.4); 1.8 (0.9)* | 1.8 (1.3–2.6); 1.9 (1.0)* |
HDL-c (mmol/L) | 1.1 (0.9–1.3); 1.1 (0.3)* | 1.1 (0.9–1.3); 1.1 (0.3)* |
LDL-c (mmol/L) | 1.9 (1.5–2.3); 1.9 (0.8)* | 2.1 (1.6–2.6); 2.0 (0.8)* |
SHBG (nmol/L) | 27 (19–41); 27 (16)* | NA |
Fasting C-peptide (pmol/L) | 1,150 (820–1,460); 1,090 (480)* | NA |
HOMA2-%B | 54 (37–73); 51 (27)* | NA |
HOMA2-IR | 3.1 (2.3–4.2); 3.1 (1.5)* | NA |
UCPCR (nmol/mmol) | 3.4 (2.0–5.0); 3.0 (2.3)* | NA |
eGFR (mL/min/1.73 m2) | 85 (70–98); 85 (24) | 82 (66–97); 82 (23) |
GAD or IA2 positive, % | 3 | NA |
Therapy | ||
Number of concomitant therapies at therapy start, % of total | ||
0 | 3 | 6 |
1 | 35 | 51 |
2 | 57 | 42 |
3+ | 5 | 2 |
DPP-4 type, % of total | ||
Sitagliptin | 87 | 72 |
Alogliptin | 0 | 2 |
Linagliptin | 4 | 10 |
Saxagliptin | 6 | 12 |
Vildagliptin | 2 | 4 |
. | PRIBA (n = 254) . | CPRD (n = 23,001) . |
---|---|---|
Characteristics | ||
Baseline HbA1c (mmol/mol) | 74 (12) | 72 (15) |
Baseline HbA1c (%) | 8.9 (1.1) | 8.7 (1.3) |
Age at therapy start (years) | 63 (10) | 64 (11) |
Age at diagnosis (years) | 54 (10) | 56 (10) |
Male sex, % | 63 | 61 |
Duration of diabetes (years) | 9 (6) | 8 (5) |
BMI | 32 (29–37); 33 (6) | 32 (28–36); 33 (6) |
Ethnicity, % | ||
White | 97 | 45 |
Nonwhite | 3 | 6 |
Missing | 0 | 49 |
Biomarkers | ||
Triglycerides (mmol/L) | 1.7 (1.2–2.4); 1.8 (0.9)* | 1.8 (1.3–2.6); 1.9 (1.0)* |
HDL-c (mmol/L) | 1.1 (0.9–1.3); 1.1 (0.3)* | 1.1 (0.9–1.3); 1.1 (0.3)* |
LDL-c (mmol/L) | 1.9 (1.5–2.3); 1.9 (0.8)* | 2.1 (1.6–2.6); 2.0 (0.8)* |
SHBG (nmol/L) | 27 (19–41); 27 (16)* | NA |
Fasting C-peptide (pmol/L) | 1,150 (820–1,460); 1,090 (480)* | NA |
HOMA2-%B | 54 (37–73); 51 (27)* | NA |
HOMA2-IR | 3.1 (2.3–4.2); 3.1 (1.5)* | NA |
UCPCR (nmol/mmol) | 3.4 (2.0–5.0); 3.0 (2.3)* | NA |
eGFR (mL/min/1.73 m2) | 85 (70–98); 85 (24) | 82 (66–97); 82 (23) |
GAD or IA2 positive, % | 3 | NA |
Therapy | ||
Number of concomitant therapies at therapy start, % of total | ||
0 | 3 | 6 |
1 | 35 | 51 |
2 | 57 | 42 |
3+ | 5 | 2 |
DPP-4 type, % of total | ||
Sitagliptin | 87 | 72 |
Alogliptin | 0 | 2 |
Linagliptin | 4 | 10 |
Saxagliptin | 6 | 12 |
Vildagliptin | 2 | 4 |
Data are median (interquartile range) or mean (SD) unless otherwise specified. NA, not available.
*Log-transformed.